Placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks with no evidence of weight loss plateau in ACCESS II, demonstrating highest efficacy among oral ...

Structure Therapeutics (GPCR) stock jumped 10% after its GLP-1 pill aleniglipron posted 16.3% weight loss, outperforming Lilly and Novo's oral candidates.

“The consistent weight loss observed across multiple studies to date reaffirms aleniglipron’s potential to be a best-in-class oral GLP-1, with injectable-like efficacy that could become a backbone ...

Nvidia will structure hundreds of zettabytes per year of unstructured data to make it the ground truth for AI. AI will ...

Testing revealed weight loss effects some Wall Street analysts believe compare favorably to Lilly’s orforglipron, which ...

Structure Therapeutics’ oral obesity drug elicited a placebo-adjusted weight loss of 16.3% at 44 weeks in a Phase 2 trial.

Scientists at the Department of Energy's Lawrence Berkeley National Laboratory (Berkeley Lab) have developed a new way to determine atomic structures from nanocrystals previously considered unusable, ...

An experimental obesity pill from Structure Therapeutics helped patients lose significant weight in a mid-stage trial, with a Phase 3 study in the works.

What do you get when you combine distressed offshore wind energy sites, surging AI energy demands, and not-in-my-backyard sentiments towards data centers? One company is combining all three problems ...

Finance leaders across APAC face growing compliance pressure as fragmented systems create data integrity risks in multi-entity financial reporting.

Current and wave measurements provide essential data for evaluating how water movement affects coastal infrastructure ...